HIGHTIDE-B (02511.HK): Terminates Acting-in-Concert Agreement

NewTimeSpace News: On 30 October 2026, HighTide Therapeutics, Inc. (stock code: 02511) voluntarily announced that Dr Liu Liping, Founder BVI, Guangyuan International Investment, ZT Global Energy and Yuejun have entered into a termination agreement to terminate their acting-in-concert agreement dated 30 September 2021, effective 30 October 2026.

The announcement stated that, immediately before the termination, Founder BVI, Guangyuan International Investment, ZT Global Energy and Yuejun were respectively entitled to exercise about 12.09%, 0.78%, 0.95% and 0.00% of the total issued shares. Founder BVI, as part of the assets constituting Dr Liu's family trust, is wholly owned by the family trust; as the investment adviser of the family trust, Dr Liu is entitled to exercise the voting rights attached to the 81,000,000 shares held by Founder BVI. Together with the voting rights attached to 34,911,308 shares held by the employee share scheme platforms in respect of vested awards, the AIC Group was entitled to exercise about 19.03% of the total voting rights and was regarded as the single largest shareholder group.

The company said that, after the termination agreement takes effect, the parties are no longer acting in concert and may exercise their voting and other shareholder rights independently. Notwithstanding the termination, Dr Liu Liping remains the single largest shareholder, entitled to exercise about 17.30% of the voting rights. The board believes the matter will not have any material adverse impact on the group's operations.